- Home
- TLPH
TLPH
Talphera Inc.
as 11-25-2024 10:40am EST
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | 13.4M | IPO Year: | 2011 |
| Target Price: | $4.50 | AVG Volume (30 days): | 67.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $1.61 | Next Earning Date: | 11-13-2024 |
| Revenue: | $281,000 | Revenue Growth: | -24.05% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Talphera Inc. (TLPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | TLPH | CHIEF EXECUTIVE OFFICER | Aug 30 '24 | Buy | $1.05 | 7,260 | $7,598.32 | 198,066 |
Latest Talphera Inc. News
TLPH Breaking Stock News: Dive into TLPH Ticker-Specific Updates for Smart Investing
PR Newswire
16 hours ago
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Simply Wall St.
9 days ago
Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023)
GuruFocus.com
11 days ago
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
PR Newswire
12 days ago
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
19 days ago
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
PR Newswire
2 months ago
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
PR Newswire
3 months ago
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR Newswire
3 months ago
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Compare TLPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TLPH Talphera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.